Skip to main
We’re doing some system maintenance
    2. /
  2. Stocks
    3. /
  3. Endocyte
ECYT

Buy Endocyte (ECYT) Stock

ECYT
See ECYT stock price and Buy/Sell Endocyte with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
ECYT

Endocyte (ECYT)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Endocyte (ECYT)

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chem...Read more
Market Cap
$1.96B
1 Year High
$24
Volume
—
1 Year Low
$2.81
Price to Earnings Ratio
—
Open
—
Dividend Rate
—
High
—
Dividend Yield
—
Low
—

Community

People who own or watch ECYT stock

Endocyte Stock Rating

What analysts recommend for ECYT stock, on a scale from 1(buy) to 5(sell).
Buy2.3 / 5
BuyHoldSell

Endocyte Stock Earnings

The value each ECYT share was expected to gain vs. the value that each ECYT share actually gained.
Expected
Actual

Frequently Asked Questions (FAQ)

As of Sep 26, 2022, the market cap for Endocyte stock is $1.96B

The 52-week high for Endocyte stock is $24. The current Endocyte stock price $0 is 100.00% below its 52-week high

The 52-week low for Endocyte stock is $2.81. The current Endocyte stock price $0 has increased 100.00% from its 52-week low

No, the Endocyte stock does not pay dividends to its shareholders

The target price for Endocyte stock is $24 based on the average of what a group of analyst think Endocyte stock could be worth at a future date. This is not a prediction by Public.com

Buy Endocyte (ECYT) Stock

ECYT
See ECYT stock price and Buy/Sell Endocyte with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch ECYT stock
  • 444444444 avatar
  • alexasgari avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.

View Full Disclosures